GLUR3: A Potential Drug Target for Neurological Disorders (G2899)

Target Name: GRIK3

NCBI ID: G2899

GRIK3

GLUR3: A Potential Drug Target for Neurological Disorders

GRIK3 (gluR-7) is a protein that is expressed in various tissues of the body, including the brain, spinal cord, and peripheral nerves. It is a member of the GLUR family of proteins, which are involved in the regulation of neurotransmitter signaling. GRIK3 has been identified as a potential drug target or biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

The GLUR family of proteins is characterized by the presence of a Glu-215 amino acid residue, which is involved in the formation of a disulfide bond. This structural feature allows the GLUR proteins to form a dimeric species, which can enhance their ability to interact with other proteins. GRIK3 is a 12-kDa protein that consists of two distinct N-terminal regions and a C-terminal region. The N-terminal region consists of a unique Glu-215 residue, which is surrounded by a short amino acid sequence that is involved in the formation of a disulfide bond. The C-terminal region consists of a Glu-215 residue, which is surrounded by a longer amino acid sequence that is involved in the formation of a disulfide bond.

GRIK3 is expressed in various tissues of the body, including the brain, spinal cord, and peripheral nerves. It is highly expressed in the brain, where it is found in the postsynaptic density of dendrites in neurons. GRIK3 is also expressed in the spinal cord, where it is involved in the regulation of pain signaling. In addition, GRIK3 is expressed in the peripheral nerves, where it is involved in the regulation of neurotransmission.

GRIK3 has been identified as a potential drug target or biomarker for various neurological and psychiatric disorders. For example, GRIK3 has been shown to be involved in the regulation of neurotransmission in the brain, which is thought to be involved in the development of Alzheimer's disease. Studies have shown that mice that have been genetically modified to lack GRIK3 have reduced levels of neurotransmitters in the brain, which is consistent with the hypothesis that GRIK3 is involved in the regulation of neurotransmission in the brain.

In addition, GRIK3 has also been shown to be involved in the regulation of pain signaling in the brain. Studies have shown that GRIK3 is involved in the regulation of pain signaling in the brain by modulating the levels of neurotransmitters such as calcitonin and depressin. These studies suggest that GRIK3 may be a potential drug target or biomarker for pain disorders.

GRIK3 has also been shown to be involved in the regulation of neurotransmission in the spinal cord. Studies have shown that mice that have been genetically modified to lack GRIK3 have reduced levels of neurotransmitters in the spinal cord, which is consistent with the hypothesis that GRIK3 is involved in the regulation of neurotransmission in the spinal cord.

In addition, GRIK3 has also been shown to be involved in the regulation of neurotransmission in the peripheral nerves. Studies have shown that GRIK3 is involved in the regulation of neurotransmission in the peripheral nerves by modulating the levels of neurotransmitters such as acetylcholine and neurotensin. These studies suggest that GRIK3 may be a potential drug target or biomarker for neurotransmission disorders in the peripheral nerves.

GRIK3 has also been shown to be involved in the regulation of cell signaling in various tissues of the body. Studies have shown that GRIK3 is involved in the regulation of cell signaling in the brain by modulating the levels of neurotransmitters such as dopamine and GABA. These studies suggest that GRIK3 may be a potential drug target or biomarker for

Protein Name: Glutamate Ionotropic Receptor Kainate Type Subunit 3

Functions: Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. This receptor binds domoate > kainate >> L-glutamate = quisqualate >> AMPA = NMDA

The "GRIK3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GRIK3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets